ADMA Biologics Inc (NASDAQ:ADMA) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• ADMA Biologics has a consensus analyst rating of “Moderate Buy” from six analysts, with an average 12-month price target of about $18.67.
• Recent analyst actions have been mixed: Raymond James started coverage with an outperform rating and a $21 target, while other firms adjusted ratings and targets, including Mizuho cutting its target to $17.
• The stock traded at $8.59 and is down from its 52-week high, while the company also faces securities class-action attention tied to allegations about revenue growth and channel stuffing, which may weigh on sentiment.

Shares of ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $18.6667.

ADMA has been the subject of several recent analyst reports. Raymond James Financial began coverage on shares of ADMA Biologics in a research note on Wednesday, June 10th. They set an "outperform" rating and a $21.00 target price for the company. Wall Street Zen lowered ADMA Biologics from a "buy" rating to a "hold" rating in a report on Monday, May 4th. Mizuho cut their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating on the stock in a report on Wednesday, July 15th. Zacks Research raised ADMA Biologics from a "strong sell" rating to a "hold" rating in a report on Monday, July 6th. Finally, Cantor Fitzgerald reiterated a "neutral" rating on shares of ADMA Biologics in a research note on Thursday, March 26th.

Insider Activity at ADMA Biologics

In related news, Director Jerrold B. Grossman bought 12,500 shares of the stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the acquisition, the director owned 513,884 shares in the company, valued at $4,116,210.84. This represents a 2.49% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Summit Securities Group LLC acquired a new position in shares of ADMA Biologics in the 4th quarter valued at about $29,000. Western Wealth Management LLC purchased a new position in ADMA Biologics in the first quarter valued at approximately $31,000. iSAM Funds UK Ltd acquired a new position in ADMA Biologics during the third quarter valued at approximately $34,000. Optima Capital LLC purchased a new stake in ADMA Biologics during the 4th quarter worth $36,000. Finally, Morse Asset Management Inc acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at about $44,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Stock Down 1.8%

Shares of NASDAQ:ADMA opened at $8.59 on Wednesday. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $20.46. The firm's 50 day moving average price is $8.48 and its 200 day moving average price is $12.10. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of 12.63 and a beta of 0.73.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, hitting the consensus estimate of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The company had revenue of $114.49 million during the quarter, compared to analysts' expectations of $139.98 million. During the same quarter in the previous year, the business posted $0.11 EPS. The firm's revenue was down .3% on a year-over-year basis. As a group, equities research analysts predict that ADMA Biologics will post 0.8 earnings per share for the current fiscal year.

Key ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
• Neutral Sentiment: Multiple law firms, including Rosen, Pomerantz, Portnoy, Faruqi & Faruqi, and others, issued reminders about the upcoming lead-plaintiff deadline in the ADMA securities class action. Article Title
• Neutral Sentiment: Several reports repeated the allegation that ADMA’s reported revenue growth may have been inflated by channel stuffing, but these are legal claims rather than new company disclosures. Article Title
• Negative Sentiment: The securities-fraud lawsuit and the associated publicity create legal and reputational risk, which can weigh on sentiment until the case is resolved. Article Title

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.